By the Top Tier Newswire AI Desk · September 17, 2026 at 10:26 AM ET · reviewed against 3 wire stories
ABCELLERA BIOLOGICS (ABCL) is up +10.20% in the latest session. Our newswire has captured 3 stories on ABCL across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABCL stock rose 10.20% to $12.86 on Tuesday, driven by the announcement that AbCellera Biologics will present Phase 2 data for ABCL635 at the IMS 20th World Congress on Menopause in October 2026. The news, highlighted across multiple sources, lifted investor sentiment and triggered a strong intraday rally. The stock opened with a modest 1.7% gap up and climbed further to a session high of $12.92 before settling at $12.86.
What Happened
AbCellera Biologics announced it will present Phase 2 efficacy and safety data for ABCL635 at the IMS 20th World Congress on Menopause in Rio de Janeiro, with the presentation scheduled for October 1, 2026. This update is the first major clinical milestone for the drug candidate and has drawn attention from the biotech sector. The company has positioned ABCL635 as a potential treatment for menopause symptoms, and the upcoming data presentation is seen as a key step in its development timeline. The news came amid a broader market move that included other biotech and tech stocks rising on Tuesday.
What The Data Shows
The stock opened at $11.87, a 1.7% gap up from the prior close of $11.67, and surged to a high of $12.92 during the session. Trading volume reached 2.0 million shares, which is 0.3 times the 3-month daily average. The stock closed at $12.86, near its session high. Over the last 8 sessions, ABCL has moved up 0.7% from $11.44 to $11.52. Recent insider activity has been positive, with four purchases totaling $1.5 million reported in the last 90 days, most recently on August 24, 2026. On September 17, the stock printed 14 fresh 52-week highs and four fresh 52-week lows.
What To Watch
The upcoming presentation of Phase 2 data for ABCL635 at the IMS World Congress on Menopause in October 2026 is the key event to monitor. Investors will be watching for clarity on the drug’s efficacy and safety profile, which could influence further market reactions and the company’s development plans.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ABCL · today's session (5-min) · +9.90% vs prior close · updated 1:53 PM ETAI sentiment, last 36h · averaged over 3 stories · 60/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
7h agoMarketChameleonBULLISH 63Product/PR
AbCellera Sets October 2026 Spotlight for ABCL635 Phase 2 Menopause Symptom Data
September 17, 2026
AbCellera said it will present Phase 2 efficacy and safety data for ABCL635 in an oral session at the IMS 20th World Congress on Menopause in Rio de Janeiro, with the talk scheduled for October 1, 2026. The company is positioning ABCL635 as a non-hormonal, long-acting NK3R-targeting monoclonal antibody for moderate-to-severe vasomotor symptoms, a condition it estimates affects up to 80% of women and roughly 12 million U.S. women at moderate-to-severe levels.
22h agoThe FlyBULLISH 59Product/PR
AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause
23h agoStockTitanBULLISH 59Product/PR
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →